Author

Mark W. Surber

Observed names: M Surber, M. Surber, Mark Surber, Mark W Surber, Surber, Mark

Observed institutions: Hospital for Sick Children, KU Leuven

ORCID: 0000-0001-8868-9233

Observed ORCID: 0000-0001-8868-9233

OpenAlex ID: A5014092211

Hypoxia Inducible Factor 1A Supports a Pro-Fibrotic Phenotype Loop in Idiopathic Pulmonary Fibrosis

2021 · Gali Epstein Shochet, Becky Bardenstein-Wald, et al. · International Journal of Molecular Sciences · 61

Inhaled nintedanib is well-tolerated and delivers key pharmacokinetic parameters required to treat bleomycin-induced pulmonary fibrosis

2020 · Mark W. Surber, Steve Beck, et al. · Pulmonary Pharmacology & Therapeutics · 44

A Randomized, Double-Blinded, Placebo-Controlled, Dose-Escalation Phase 1 Study of Aerosolized Pirfenidone Delivered via the PARI Investigational eFlow Nebulizer in Volunteers and Patients with Idiopathic Pulmonary Fibrosis

2019 · Jun Keng Khoo, A. Bruce Montgomery, et al. · Journal of Aerosol Medicine and Pulmonary Drug Delivery · 39

Aerosol Pirfenidone Pharmacokinetics after Inhaled Delivery in Sheep: a Viable Approach to Treating Idiopathic Pulmonary Fibrosis

2019 · Lisa M Kaminskas, Cornelia B Landersdorfer, et al. · Pharmaceutical Research · 34

Single-dose pharmacokinetics of aerosol MP-376 (levofloxacin solution for inhalation) in cystic fibrosis patients: PK-PD implications

2008 · P.C. Griffith, C. Hansen, et al. · Journal of Cystic Fibrosis · 28

Inhalation: A means to explore and optimize nintedanib's pharmacokinetic/pharmacodynamic relationship

2020 · Gali Epstein-Shochet, Stephen Pham, et al. · Pulmonary Pharmacology & Therapeutics · 27

Pharmaceutical industry, academia and patient advocacy organizations: What is the recipe for synergic (win–win–win) collaborations?

2015 · Daniel M. Rose, Richard Marshall, et al. · Respirology · 16

Nebulization of the acidified sodium nitrite formulation attenuates acute hypoxic pulmonary vasoconstriction

2010 · Bakytbek Egemnazarov, Ralph T Schermuly, et al. · Respiratory Research · 16

Galectin-3 levels are elevated following nintedanib treatment

2020 · Gali Epstein Shochet, Alon Pomerantz, et al. · Therapeutic Advances in Chronic Disease · 9

Inhaled Nintedanib (AP02) for the Treatment of IPF: Safety, Tolerability, and Pharmacokinetics After Single Ascending Doses to Healthy Subjects and IPF Patients

2025 · M. Palacios, S. Pham, et al. · American Journal of Respiratory and Critical Care Medicine · 2

Direct Lung Administration of Nintedanib Reduces Lung Fibrosis in a Multi-Challenge Bleomycin Rat Model

2020 · M.C. McElroy, S. Beck, et al. · American Journal of Respiratory and Critical Care Medicine · 1

Pharmacokinetics and Safety of Pirfenidone Following Inhaled Delivery to Sheep: A Viable Approach to Treating Idiopathic Pulmonary Fibrosis

2019 · M. Surber, L. Kaminskas, et al. · American Journal of Respiratory and Critical Care Medicine · 1

Nebulized nintedanib (AP02) for idiopathic pulmonary fibrosis demonstrates favorable safety and lung lining fluid exposures: results from two phase I safety, tolerability, and pharmacokinetics studies

2026 · Michelle Palacios, Rebecca Boone, et al. · Respiratory Research

Long-term Safety Data of Inhaled Pirfenidone (AP01) in Idiopathic Pulmonary Fibrosis (IPF) and Non-IPF Interstitial Lung Disease (ILD) Patients

2023 · F.A. Woodhead, D. Nair, et al. · American Journal of Respiratory and Critical Care Medicine

Galectin-3 is elevated following nintedanib treatment

2021 · G Epstein Shochet, A Pomerantz, et al. · 12.01 - Idiopathic interstitial pneumonias

Works count: 18

Citation count: 280

H-index: 9

I10-index: 8